

FOI – 2262

19th March 2024

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

Q1. How many patients were treated in February 2024 (or latest available month) by the Dermatology department with the following drugs:

Abrocitinib (Cibinqo) -	0
Baricitinib (Olumiant) -	1
Dupilumab (Dupixent) -	102
Lebrikizumab (Ebglyss) -	0
Omalizumab (Xolair) -	34
Tralokinumab (Adtralza) -	2
Upadacitinib (Rinvoq) -	17

Q2. How many patients were treated in February 2024 (or latest available month) by the Respiratory Medicine departments with the following drugs:

Benralizumab (Fasenra)
Dupilumab (Dupixent)
Mepolizumab (Nucala)
Omalizumab (Xolair)
Reslizumab (Cinqaero)
Tezepelumab (Tezspire)

Response:

All the respiratory is done via the tertiary centre in BHSCT.

The information you require may be held by the Belfast Health & Social Care Trust.

You can contact them at:

Public Liaison
Belfast HSC Trust
1st Floor, Nore Villa
Knockbracken Healthcare Park
Belfast, BT8 8BH

Email: publicliaison@belfasttrust.hscni.net

Email: foi.team@southerntrust.hscni.net